CD274 and breast carcinoma: Drugs like Pembrolizumab, Nivolumab, Avelumab, Atezumab, and Durvalumab have been created for breast cancer immunotherapy, but their effectiveness is restricted by PD-1/PD-L1 expression, limiting the number of patients who can benefit from them (25, 26).